Abbvie Inc. · NYSE:ABBV
Abbvie — Jefferies Healthcare Conference 2017
9 slides from Abbvie's conference presentation, Jun 8, 2017
Slide 1: Jefferies Healthcare Conference
Jefferies Healthcare Conference June 8, 2017 Jefferies Healthcare Conference | June 8, 2017 |© 2017 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, gen
Slide 3: Key Pipeline Events in 2017
Key Pipeline Events in 2017 Regulatory Approvals, Submissions & Registrational Study Milestones Regulatory Approvals Regulatory Submissions • Imbruvica for 2L+ MZL • Imbruvica for 2L+ cGvHD • Imbruvica for 2L+ cGvHD • Venclexta for r/r CLL • G/P Next-Gen HCV • Elagolix for endometriosis Phase 3
Slide 4: SELECT Phase 3 Program for Upadacitinib in Rheumatoid Arthritis
SELECT Phase 3 Program for Upadacitinib in Rheumatoid Arthritis One of the most robust Phase 3 programs for RA ‒ 6 studies, nearly 4,800 patients, multiple patient types, 2 biologic comparators Patient csDMARD-IR MTX-naïve MTX-IR MTX-IR Biologic-IR Biologic-IR Population Scheme Combo Mono Combo Mono
Slide 5: SELECT-NEXT Trial Demonstrates Compelling Data in csDMARD-IR Patients
SELECT-NEXT Trial Demonstrates Compelling Data in csDMARD-IR Patients 70% 60% Patient 50% csDMARD-IR Population 40% Scheme Combo 30% Background csDMARDs 20% Active None Comparator Study 10% 12 weeks Duration 0% Signs and Endpoints ACR20 ACR50 ACR70 LDA* Remission* Symptoms Upadacitinib 15mg QD Upada
Slide 6: Key Efficacy Parameters in csDMARD-IR Studies for Selective JAK Inhibitors
Key Efficacy Parameters in csDMARD-IR Studies for Selective JAK Inhibitors - Placebo-adjusted week 12 results in Phase 3 studies 35% 30% 25% 20% 15% 10% 5% 0% ACR20 ACR50 ACR70 LDA Remission DAS28 (CRP) DAS28 (CRP) Upadacitinib 15mg QD Upadacitinib 30mg QD Baricitinib 2mg QD Baricitinib 4mg QD Upada
Slide 7: Upadacitinib Upcoming Milestone
Upadacitinib Upcoming Milestone Compelling data to-date; Significant potential across rheum, derm and gastro indications 2017 2018 1H 2H 1H 2H RA RA RA RA RA SELECT SELECT SELECT SELECT SELECT NEXT data BEYOND data MONO data COMPARE data EARLY data RA Regulatory Submission in 2018 PsA AxSpA Ph3 star
Slide 8: Key Pipeline Events in 2017
Key Pipeline Events in 2017 Regulatory Approvals, Submissions & Registrational Study Milestones Regulatory Approvals Regulatory Submissions • Imbruvica for 2L+ MZL • Imbruvica for 2L+ cGvHD • Imbruvica for 2L+ cGvHD • Venclexta for r/r CLL • G/P Next-Gen HCV • Elagolix for endometriosis Phase 3
Slide 9: Qobvie
Qobvie